About 200 reports

  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H2 2017
  • PTX-15 - DRUG PROFILE

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Pharmaceutical
  • Specialty Hospital
  • Targeted Therapy
  • Astellas Pharma Inc.
  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H1 2018
  • HEART TRANSPLANT REJECTION - PIPELINE BY NOXXON PHARMA AG, H1 2018

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 111 Trial Title

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* HEART TRANSPLANT REJECTION

  • Clinical Trial
  • Pharmaceutical
  • Specialty Hospital
  • Targeted Therapy
  • Novartis AG
  • Actual/Estimate d End Date
  • MAY 14, 2018: CYTOSORB ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

Severe vasoplegia (i. e. critically low blood pressure due to a loss of vascular resistance despite high cardiac output) is one of the most dangerous adverse events that occurs in up to ##% of patients following heart transplantation.

  • Hospital
  • Specialty Hospital
  • United States
  • Demand
  • CytoSorbents Corporation
  • Clinical Trial Status
  • CYTOSORB - REMOVAL OF CYTOKINES IN PATIENTS UNDERGOING CARDIAC SURGERY WITH CPB (THE REMOTE STUDY)

According to the Organ Procurement and Transplantation Network (OPTN), there were more than ##, ## heart transplants in the United States in 2017, up approximately ##% in the past decade, and more than ##, ## heart transplants worldwide each year.

  • Blood Supply
  • Clinical Trial
  • Specialty Hospital
  • Targeted Therapy
  • CytoSorbents Corporation

One year after the patients cardiac arrests, the researchers assessed survivors with the Cerebral Performance Category (CPC) Scale, a commonly used measure of neurological function following cardiac arrest.

  • Hospital
  • Specialty Hospital
  • Targeted Therapy
  • United States
  • Company
  • 7.4.1 RISING DISEASE PREVALENCE AND NEED FOR ORGAN DONATIONS
  • AUTOTRANSFUSION SYSTEMS MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2017-2024 (USD MILLION)

TABLE ## Lung, orthotropic liver transplantation (LT), kidney, and heart transplantation are the most common procedures in this segment.

  • Specialty Hospital
  • Transplantation
  • North America
  • United States
  • Fresenius Group
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Immunotherapy
  • Oncology
  • Specialty Hospital
  • Targeted Therapy
  • Apexigen, Inc.

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Pharmaceutical
  • Specialty Hospital
  • Targeted Therapy
  • World
  • 7.1 INTRODUCTION
  • Other Applications

Other applications include heart transplants and cardiomyoplasty.

  • Specialty Hospital
  • North America
  • United States
  • World
  • B. Braun Melsungen AG
  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Cell Therapy
  • Healthcare
  • Specialty Hospital
  • Targeted Therapy
  • Product Initiative

CLINICAL TRIALS BY PHASE IN G## COUNTRIES LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINIC

  • Clinical Trial
  • Monoclonal Antibody
  • Specialty Hospital
  • Targeted Therapy
  • Novartis AG

The prominent features of this report are - ##.

  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Ophthalmology
  • Specialty Hospital
  • Targeted Therapy
  • Novartis AG
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Medical Biotechnology
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..4), H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

MP## is currently in phase ##.

  • Immunotherapy
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Apexigen, Inc.

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Clinical Trial
  • Immunology
  • Specialty Hospital
  • Targeted Therapy
  • Novartis AG
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Pharmaceutical
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative
  • DORMANT PRODUCTS, H2 2019 (CONTD..1), H2 2019

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Immunotherapy
  • Oncology
  • Specialty Hospital
  • Targeted Therapy
  • Apexigen, Inc.

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor

  • Monoclonal Antibody
  • Pharmaceutical
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Clinical Trial profile. 96 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative
  • Novartis AG

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Clinical Trial
  • Liver Transplant
  • Specialty Hospital
  • Targeted Therapy
  • Novartis AG
  • Deal Rationale

The center provides transplantation services such as auto islet transplant, corneal transplant, face transplantation program, heart transplant, hand transplant program, intestinal transplant and others.

  • Health Services
  • Specialty Hospital
  • United States
  • Company Financials
  • Select Medical Corporation
  • MAY 08, 2018: CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

It is one of the largest kidney dialysis companies in the world.

  • Specialty Hospital
  • Targeted Therapy
  • United States
  • Demand
  • CytoSorbents Corporation

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Alexion Pharmaceuticals Inc ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## Cytokinetics Inc ## ## ## ## ## ## ## Quintiles IMS Holdings Inc ## ## ## ## ## ## ## CuraVac Inc ## ## ## ## ## ## ## CSL Ltd ##

  • Monoclonal Antibody
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Autoimmune Disease
  • Specialty Hospital
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

The prominent features of this report are - ##.

  • Digestive System Disorder
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd arGEN-X BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Applied BioMath LLC ## ## ## ## ## Amgen Inc ## ## ## ## ## Almirall SA Source: GlobalData' s Pharma Intelligence C

  • Autoimmune Disease
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## Clinical Research and Biosciences India Private Limited (Inactive) ## ## ## ## ## ## ClinAssess GmbH ## ## ## ## ## ## Bavarian Nordic A/ S ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## APT

  • Pharmaceutical
  • Specialty Hospital
  • Targeted Therapy
  • World
  • Product Initiative
  • MAY 08, 2018: CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

Each unit will consist of one share of common stock and one warrant to purchase ##. ## shares of common stock.

  • Medical Device
  • Specialty Hospital
  • United States
  • Demand
  • CytoSorbents Corporation